[HTML][HTML] Chlamydia trachomatis Cross-Serovar Protection during Experimental Lung Reinfection in Mice

C Lanfermann, M Kohn, R Laudeley, C Rheinheimer… - Vaccines, 2021 - mdpi.com
Chlamydia trachomatis causes most bacterial sexually transmitted diseases worldwide.
Different major outer membrane proteins (MOMPs) define various serovars of this …

A new murine model for testing vaccines against genital Chlamydia trachomatis infections in males

S Pal, AK Sarcon, LM De la Maza - Vaccine, 2010 - Elsevier
Two groups of 50 BALB/c male mice were immunized with live Chlamydia trachomatis
mouse pneumonitis (MoPn) using the intranasal (in) or the meatus urethra (intraurethral: iu) …

Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization

P Ralli-Jain, D Tifrea, C Cheng, S Pal, LM De la Maza - Vaccine, 2010 - Elsevier
Chlamydia trachomatis causes respiratory and sexually transmitted infections. Here, we
tested a vaccine formulated with the recombinant major outer membrane protein from C …

[HTML][HTML] Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine

RC Brunham, J Rey-Ladino - Nature reviews immunology, 2005 - nature.com
Sexually transmitted Chlamydia trachomatis infections are a serious public-health problem.
With more than 90 million new cases occurring annually, C. trachomatis is the most common …

Immunity to murine chlamydial genital infection

RP Morrison, HD Caldwell - Infection and immunity, 2002 - Am Soc Microbiol
Chlamydia trachomatis sexually transmitted infections cause considerable morbidity and
socioeconomic burden worldwide, despite significant advances in our understanding of the …

Prior Genital Tract Infection with a Murine or Human Biovar of Chlamydia trachomatis Protects Mice against Heterotypic Challenge Infection

KH Ramsey, TW Cotter, RD Salyer… - Infection and …, 1999 - Am Soc Microbiol
We sought to assess the degree of cross-protective immunity in a mouse model of
chlamydial genital tract infection. Following resolution of genital infection with the mouse …

A Recombinant Chlamydia trachomatis MOMP Vaccine Elicits Cross-serogroup Protection in Mice Against Vaginal Shedding and Infertility

DF Tifrea, S Pal, LM de la Maza - The Journal of Infectious …, 2020 - academic.oup.com
Background Chlamydia trachomatis is the most common sexually transmitted bacterial
pathogen worldwide. Here, we determined the ability of a C. trachomatis recombinant major …

The mouse model of Chlamydia genital tract infection: a review of infection, disease, immunity and vaccine development

CP O'Meara, DW Andrew… - Current molecular …, 2014 - ingentaconnect.com
Chlamydia trachomatis is the most common sexually transmitted bacterial infection
worldwide. The impact of this pathogen on human reproduction has intensified research …

Characterization of protective immune responses promoted by human antigen targets in a urogenital Chlamydia trachomatis mouse model

AW Olsen, P Andersen, F Follmann - Vaccine, 2014 - Elsevier
A vaccine against genital tract infections caused by Chlamydia trachomatis is urgently
needed. We have previously identified a number of immunodominant human T-and/or B-cell …

[HTML][HTML] Acquired homotypic and heterotypic immunity against oculogenital Chlamydia trachomatis serovars following female genital tract infection in mice

JM Lyons, SA Morré, LP Airo-Brown, AS Peña… - BMC Infectious …, 2005 - Springer
Background Chlamydia trachomatis is the most common sexually transmitted bacterial
pathogen causing female genital tract infection throughout the world. Reinfection with the …